Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

BACKGROUND: We present the first report comparing early toxicity outcomes with high-dose rate brachytherapy (HDR-BT) boost upfront versus intensity modulated RT (IMRT) upfront combined with androgen deprivation therapy (ADT) as definitive management for intermediate risk or higher prostate cancer. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Amit, Brenneman, Randall J., Hogan, Jacob, Barnes, Justin M., Huang, Yi, Morris, Robert, Goddu, Sreekrishna, Altman, Michael, Garcia-Ramirez, Jose, Li, Harold, Zoberi, Jacqueline E., Bullock, Arnold, Kim, Eric, Smith, Zachary, Figenshau, Robert, Andriole, Gerald L., Baumann, Brian C., Michalski, Jeff M., Gay, Hiram A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182264/
https://www.ncbi.nlm.nih.gov/pubmed/34136665
http://dx.doi.org/10.1016/j.ctro.2021.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182264/
https://www.ncbi.nlm.nih.gov/pubmed/34136665
http://dx.doi.org/10.1016/j.ctro.2021.05.004

Ejemplares similares